Switch theme
Sign up to access all valuation multiples
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
2000
111
LTM Revenue $21.8M
LTM EBITDA -$16.3M
$205M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MediWound has a last 12-month revenue (LTM) of $21.8M and a last 12-month EBITDA of -$16.3M.
In the most recent fiscal year, MediWound achieved revenue of $20.2M and an EBITDA of -$27.9M.
MediWound expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MediWound valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.8M | XXX | $20.2M | XXX | XXX | XXX |
| Gross Profit | $5.1M | XXX | $2.6M | XXX | XXX | XXX |
| Gross Margin | 23% | XXX | 13% | XXX | XXX | XXX |
| EBITDA | -$16.3M | XXX | -$27.9M | XXX | XXX | XXX |
| EBITDA Margin | -75% | XXX | -138% | XXX | XXX | XXX |
| EBIT | -$21.8M | XXX | -$19.4M | XXX | XXX | XXX |
| EBIT Margin | -100% | XXX | -96% | XXX | XXX | XXX |
| Net Profit | -$26.6M | XXX | -$30.2M | XXX | XXX | XXX |
| Net Margin | -122% | XXX | -149% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MediWound's stock price is $22.
MediWound has current market cap of $237M, and EV of $205M.
See MediWound trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $205M | $237M | XXX | XXX | XXX | XXX | $-2.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MediWound has market cap of $237M and EV of $205M.
MediWound's trades at 10.2x EV/Revenue multiple, and -7.4x EV/EBITDA.
Equity research analysts estimate MediWound's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MediWound has a P/E ratio of -8.9x.
See valuation multiples for MediWound and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $237M | XXX | $237M | XXX | XXX | XXX |
| EV (current) | $205M | XXX | $205M | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBITDA | -12.6x | XXX | -7.4x | XXX | XXX | XXX |
| EV/EBIT | -9.4x | XXX | -10.6x | XXX | XXX | XXX |
| EV/Gross Profit | 40.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.9x | XXX | -7.9x | XXX | XXX | XXX |
| EV/FCF | -10.3x | XXX | -10.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMediWound's last 12 month revenue growth is 22%
MediWound's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
MediWound's rule of 40 is -4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MediWound's rule of X is -21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MediWound and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | -75% | XXX | -138% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -4% | XXX | -116% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 109% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MediWound acquired XXX companies to date.
Last acquisition by MediWound was XXXXXXXX, XXXXX XXXXX XXXXXX . MediWound acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MediWound founded? | MediWound was founded in 2000. |
| Where is MediWound headquartered? | MediWound is headquartered in United States of America. |
| How many employees does MediWound have? | As of today, MediWound has 111 employees. |
| Who is the CEO of MediWound? | MediWound's CEO is Mr. Ofer Gonen. |
| Is MediWound publicy listed? | Yes, MediWound is a public company listed on NAS. |
| What is the stock symbol of MediWound? | MediWound trades under MDWD ticker. |
| When did MediWound go public? | MediWound went public in 2014. |
| Who are competitors of MediWound? | Similar companies to MediWound include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MediWound? | MediWound's current market cap is $237M |
| What is the current revenue of MediWound? | MediWound's last 12 months revenue is $21.8M. |
| What is the current revenue growth of MediWound? | MediWound revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of MediWound? | Current revenue multiple of MediWound is 9.4x. |
| Is MediWound profitable? | Yes, MediWound is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MediWound? | MediWound's last 12 months EBITDA is -$16.3M. |
| What is MediWound's EBITDA margin? | MediWound's last 12 months EBITDA margin is -75%. |
| What is the current EV/EBITDA multiple of MediWound? | Current EBITDA multiple of MediWound is -12.6x. |
| What is the current FCF of MediWound? | MediWound's last 12 months FCF is -$19.9M. |
| What is MediWound's FCF margin? | MediWound's last 12 months FCF margin is -91%. |
| What is the current EV/FCF multiple of MediWound? | Current FCF multiple of MediWound is -10.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
